{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:53:31Z","timestamp":1794243211681,"version":"4.9.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Epidemiological data on polymyalgia rheumatica (PMR) in Germany is limited. Current national prevalence estimates are low by international standards. This study aimed to gain up-to-date data representative of Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional analysis was conducted on a sample of 4.8 million insured individuals, representative of the German population, from the InGef (Institute for Health Research Berlin GmbH) research database. Inclusion criteria were age \u226550\u2009years, continuous insurance status for a base period of 3\u2009years and for the subsequent 2\u2009years for longitudinal analysis. Results were additionally extrapolated to the German population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Each year from 2018 to 2021, around 1.7 million insured individuals were included in the study. Extrapolated to the German population in 2021, the incidence was 111\/100\u2009000 and the prevalence was 937\/100\u2009000. Diagnosis was made predominantly in outpatient settings (86.7%) most frequently by general practitioners (GP; 37.1%), internists (22.2%), rheumatologists (11.4%) and orthopaedists (10.2%). An additional 21% were referred to rheumatologists for treatment after diagnosis. Treatment was most commonly initiated by GPs, followed by rheumatologists, and included methotrexate in 19.8%. Most common comorbidities of prevalent patients comprised arterial hypertension (75.9%), dyslipidaemia (55.0%), diabetes mellitus (29.7%), osteoporosis (27.1%), coronary heart disease (23.4%) and cataract (24.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis revealed that PMR occurs more frequently in individuals aged 50 or older in Germany than previously assumed. Diagnosis is primarily made in general practice settings, with about one-third of patients being treated by rheumatologists. Comorbidities such as diabetes mellitus or cardiovascular diseases are common in the prevalent population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf367","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:54:00Z","timestamp":1751615640000},"page":"5818-5825","source":"Crossref","is-referenced-by-count":11,"title":["Frequency, diagnosis, and management of polymyalgia rheumatica in Germany\u2014database analysis of medical insurance data"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-8738","authenticated-orcid":false,"given":"Wolfgang A","family":"Schmidt","sequence":"first","affiliation":[{"name":"Rheumatology, Waldfriede Hospital , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8368-7298","authenticated-orcid":false,"given":"Marco","family":"Alibone","sequence":"additional","affiliation":[{"name":"InGef-Institute for Applied Health Research Berlin GmbH , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ludwig","sequence":"additional","affiliation":[{"name":"InGef-Institute for Applied Health Research Berlin GmbH , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Oberm\u00fcller","sequence":"additional","affiliation":[{"name":"InGef-Institute for Applied Health Research Berlin GmbH , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Karl","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , N\u00fcrnberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Terner","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , N\u00fcrnberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-2759","authenticated-orcid":false,"given":"Nils","family":"Venhoff","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Rheumatology and Clinical Immunology, Medical Center\u2014University of Freiburg , Freiburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2025110820493621900_keaf367-B1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/art.30155","article-title":"The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases","volume":"63","author":"Crowson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025110820493621900_keaf367-B2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00393-016-0105-3","article-title":"Diagnostics and treatment of polymyalgia rheumatica","volume":"75","author":"Dejaco","year":"2016","journal-title":"Z Rheumatol"},{"key":"2025110820493621900_keaf367-B3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.13525","article-title":"An update on polymyalgia rheumatica","volume":"292","author":"Lundberg","year":"2022","journal-title":"J Intern Med"},{"key":"2025110820493621900_keaf367-B4","first-page":"411","article-title":"Polymyalgia rheumatica","volume":"119","author":"Colombo","year":"2022","journal-title":"Dtsch Arztebl Int"},{"key":"2025110820493621900_keaf367-B5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025110820493621900_keaf367-B6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1055\/a-2144-8222","article-title":"Polymyalgia rheumatica: what\u2019s new?","volume":"149","author":"Schmidt","year":"2024","journal-title":"Dtsch Med Wochenschr"},{"key":"2025110820493621900_keaf367-B7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3892\/etm.2023.12242","article-title":"Polymyalgia rheumatica: an update (review)","volume":"26","author":"Florescu","year":"2023","journal-title":"Exp Ther Med"},{"key":"2025110820493621900_keaf367-B8","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025110820493621900_keaf367-B9","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025110820493621900_keaf367-B10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025110820493621900_keaf367-B11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"2025110820493621900_keaf367-B12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"2025110820493621900_keaf367-B13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13543784.2024.2366847","article-title":"Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development","volume":"33","author":"Iorio","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"2025110820493621900_keaf367-B14","doi-asserted-by":"crossref","first-page":"103590","DOI":"10.1016\/j.autrev.2024.103590","article-title":"The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: a systematic review of clinical trials","volume":"23","author":"Kawka","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2025110820493621900_keaf367-B15","author":"The Rheumatologist. Sarilumab approved for the treatment of adults with glucocorticoid-resistant PMR\u2014The Rheumatologist","year":"2023"},{"key":"2025110820493621900_keaf367-B16","author":"European Medicines Agency","year":"2024"},{"key":"2025110820493621900_keaf367-B17","doi-asserted-by":"crossref","first-page":"152260","DOI":"10.1016\/j.semarthrit.2023.152260","article-title":"Early referral of patients with suspected polymyalgia rheumatica\u2014a systematic review","volume":"63","author":"Nielsen","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2025110820493621900_keaf367-B18","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/rheumatology\/keae531","article-title":"Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic","volume":"64","author":"Cowley","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820493621900_keaf367-B19","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/ard-2023-225134","article-title":"Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group","volume":"83","author":"Keller","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025110820493621900_keaf367-B20","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/rheumatology\/keac713","article-title":"An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists","volume":"62","author":"Donskov","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820493621900_keaf367-B21","first-page":"1739","article-title":"The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94","volume":"24","author":"Gran","year":"1997","journal-title":"J Rheumatol"},{"key":"2025110820493621900_keaf367-B22","first-page":"205","article-title":"Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy","volume":"5","author":"Salvarani","year":"1987","journal-title":"Clin Exp Rheumatol"},{"key":"2025110820493621900_keaf367-B23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00393-022-01302-5","article-title":"Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany","volume":"83","author":"Albrecht","year":"2024","journal-title":"Z Rheumatol"},{"key":"2025110820493621900_keaf367-B24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","article-title":"Sampling strategy, characteristics and representativeness of the InGef research database","volume":"206","author":"Ludwig","year":"2022","journal-title":"Public Health"},{"key":"2025110820493621900_keaf367-B25","author":"Statistisches Bundesamt","year":"2021"},{"key":"2025110820493621900_keaf367-B26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/ard.2005.046912","article-title":"Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001","volume":"65","author":"Smeeth","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2025110820493621900_keaf367-B27","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","article-title":"Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study","volume":"77","author":"Partington","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025110820493621900_keaf367-B28","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of Polymyalgia Rheumatica 2000-2014 and Examination of Incidence and Survival Trends Over 45 Years: a Population-Based Study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025110820493621900_keaf367-B29","first-page":"830","article-title":"Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical features and epidemiological data","volume":"27","author":"Pamuk","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2025110820493621900_keaf367-B30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.1780340313","article-title":"Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy","volume":"34","author":"Salvarani","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2025110820493621900_keaf367-B31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/00325481.2018.1399774","article-title":"Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study","volume":"130","author":"De Socio A","year":"2018","journal-title":"Postgrad Med"},{"key":"2025110820493621900_keaf367-B32","first-page":"1326","article-title":"The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study","volume":"26","author":"Gonz\u00e1lez-Gay","year":"1999","journal-title":"J Rheumatol"},{"key":"2025110820493621900_keaf367-B33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4078\/jrd.2014.21.6.297","article-title":"Epidemiology of Polymyalgia Rheumatica in Korea","volume":"21","author":"Kim","year":"2014","journal-title":"J Rheum Dis"},{"key":"2025110820493621900_keaf367-B34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.1780380311","article-title":"Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991","volume":"38","author":"Salvarani","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2025110820493621900_keaf367-B35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","article-title":"Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015","volume":"47","author":"Crowson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025110820493621900_keaf367-B36","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00296-019-04387-5","article-title":"Prevalence of polymyalgia rheumatica in Colombia: data from the national health registry 2012-2016","volume":"39","author":"Fern\u00e1ndez-\u00c1vila","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025110820493621900_keaf367-B37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3899\/jrheum.220084","article-title":"Incidence and prevalence of polymyalgia rheumatica and giant cell arteritis in a healthcare management organization in Buenos Aires, Argentina","volume":"50","author":"Mart\u00ednez Perez","year":"2023","journal-title":"J Rheumatol"},{"key":"2025110820493621900_keaf367-B38","first-page":"92","article-title":"Incidence and prevalence of Polymyalgia Rheumatica (PMR): the importance of the epidemiological context. the Italian case","volume":"7","author":"Manzo","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"2025110820493621900_keaf367-B39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12891-016-1127-3","article-title":"The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population","volume":"17","author":"Yates","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2025110820493621900_keaf367-B40","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.24793","article-title":"Polymyalgia rheumatica prevalence in a population-based sample","volume":"61","author":"Bernatsky","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025110820493621900_keaf367-B41","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3399\/bjgp13X667231","article-title":"Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice","volume":"63","author":"Helliwell","year":"2013","journal-title":"Br J Gen Pract"},{"key":"2025110820493621900_keaf367-B42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00393-018-0476-8","article-title":"S3 guidelines on treatment of polymyalgia rheumatica: evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (\u00d6GR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations","volume":"77","author":"Buttgereit","year":"2018","journal-title":"Z Rheumatol"},{"key":"2025110820493621900_keaf367-B43","first-page":"51","article-title":"12-Month prevalence of hypertension in Germany","volume":"2","author":"Neuhauser","year":"2017","journal-title":"J Health Monit"},{"key":"2025110820493621900_keaf367-B44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/mr\/road026","article-title":"Clinical features of polymyalgia rheumatica patients in Japan: analysis of real-world data from 2015 to 2020","volume":"34","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025110820493621900_keaf367-B45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-018-1757-y","article-title":"Comorbidities in polymyalgia rheumatica: a systematic review","volume":"20","author":"Partington","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025110820493621900_keaf367-B46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4081\/reumatismo.2018.1039","article-title":"Comorbidity in polymyalgia rheumatica","volume":"70","author":"Chatzigeorgiou","year":"2018","journal-title":"Reumatismo"},{"key":"2025110820493621900_keaf367-B47","doi-asserted-by":"crossref","first-page":"105680","DOI":"10.1016\/j.jbspin.2023.105680","article-title":"Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: a cohort study using routinely collected health data","volume":"91","author":"Tanaka","year":"2024","journal-title":"Joint Bone Spine"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf367\/63691307\/keaf367.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5818\/63691307\/keaf367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5818\/63691307\/keaf367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:49:46Z","timestamp":1762652986000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/11\/5818\/8191109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,7]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf367","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,7]]}}}